These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36812271)

  • 1. A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo.
    Sazgarnia S; Layegh P; Darchini-Maragheh E; Sepehr V; Meshkat M; Fathi-Najafi S; Rahsepar S
    Acta Dermatovenerol Croat; 2022 Nov; 30(3):146-150. PubMed ID: 36812271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targets Exploration of Hydroxychloroquine for Pigmentation and Cell Protection Effect in Melanocytes: The Clue for Vitiligo Treatment.
    Xie B; Chen Y; Hu Y; Zhao Y; Luo H; Xu J; Song X
    Drug Des Devel Ther; 2022; 16():1011-1024. PubMed ID: 35411132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.
    Hamzavi I; Jain H; McLean D; Shapiro J; Zeng H; Lui H
    Arch Dermatol; 2004 Jun; 140(6):677-83. PubMed ID: 15210457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary habits in adult Japanese patients with vitiligo.
    Hamada R; Funasaka Y; Saeki H; Serizawa N; Hagino T; Yano Y; Mitsui H; Kanda N
    J Dermatol; 2024 Apr; 51(4):491-508. PubMed ID: 38421796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
    Gianfrancesco MA; Schmajuk G; Haserodt S; Trupin L; Izadi Z; Jafri K; Shiboski S; Sirota M; Dudley RA; Yazdany J
    Rheumatol Int; 2017 Oct; 37(10):1611-1618. PubMed ID: 28748425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families.
    Narita T; Oiso N; Fukai K; Kabashima K; Kawada A; Suzuki T
    Allergol Int; 2011 Dec; 60(4):505-8. PubMed ID: 21778811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases.
    van Geel N; Speeckaert M; Brochez L; Lambert J; Speeckaert R
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):741-6. PubMed ID: 23590677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Safety and Effectiveness of Decapeptide in Patients With Vitiligo: A Real-World Study.
    Sharma A; Majid I; Kumar HK; Banodkar P; Mhatre M; Mohod B; Jaiswal A
    Cureus; 2023 Jul; 15(7):e41418. PubMed ID: 37546028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors.
    Yin ZJ; Li P; Yu J; Zuo D; Fan H; Li F; Wang J; Gao F; Zhao W; Wang S; Ma S; Wang J
    Rheumatology (Oxford); 2024 Apr; ():. PubMed ID: 38588566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of age of onset on disease characteristics in non-segmental vitiligo.
    Solak B; Dikicier BS; Cosansu NC; Erdem T
    Int J Dermatol; 2017 Mar; 56(3):341-345. PubMed ID: 28054375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution patterns in generalized vitiligo.
    Speeckaert R; van Geel N
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):755-62. PubMed ID: 23651011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients.
    Zhang Z; Xu SX; Zhang FY; Yin XY; Yang S; Xiao FL; Du WH; Wang JF; Lv YM; Tang HY; Zhang XJ
    Arch Dermatol Res; 2009 Feb; 301(2):167-73. PubMed ID: 18839195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI).
    Kitchen H; Wyrwich KW; Carmichael C; Deal LS; Lukic T; Al-Zubeidi T; Marshall C; Pegram H; Hamzavi IH; King B
    Dermatol Ther (Heidelb); 2022 Jul; 12(7):1623-1637. PubMed ID: 35773559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of combination use of phenytoin cream 1% and fractional CO
    Abasifar H; Ghalamkarpour F; Diab R; Abdollahimajd F
    Dermatol Ther; 2022 Aug; 35(8):e15635. PubMed ID: 35699662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine.
    Oberkirchner U; Linder KE; Olivry T
    Vet Dermatol; 2012 Feb; 23(1):65-70, e15-6. PubMed ID: 21718370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.